Andreab Apolo News Today

Andrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.

Adjuvant pembrolizumab generated a disease-free survival benefit vs observation in patients with muscle-invasive and locally advanced urothelial carcinoma.

As longer-term data read out for established regimens in urothelial cancer and up-and-coming therapeutics inch toward approval, optimizing treatment approaches relies on buy-in from multidisciplinary teams and patients.